Bausch Health Cos Inc. (NYSE:BHC – Free Report) – Zacks Research raised their Q4 2026 earnings per share (EPS) estimates for Bausch Health Cos in a note issued to investors on Friday, September 26th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.14 for the quarter, up from their prior forecast of $1.13. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q1 2027 earnings at $0.88 EPS and FY2027 earnings at $4.38 EPS.
Get Bausch Health Cos alerts:
Separately, Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 20th. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.
Get Our Latest Report on Bausch Health Cos
Bausch Health Cos Trading Down 0.2%
Shares of BHC stock opened at $6.47 on Monday. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $9.85. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The stock’s 50-day moving average price is $6.92 and its 200-day moving average price is $6.06. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 24.89 and a beta of 0.48.
Bausch Health Cos (NYSE:BHC – Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The business had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tidal Investments LLC boosted its stake in shares of Bausch Health Cos by 2.6% during the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock worth $334,000 after acquiring an additional 1,276 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Bausch Health Cos by 2.5% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock worth $690,000 after acquiring an additional 2,552 shares in the last quarter. SBI Securities Co. Ltd. boosted its stake in shares of Bausch Health Cos by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company’s stock worth $27,000 after acquiring an additional 3,001 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares in the last quarter. Finally, State of Wyoming boosted its stake in shares of Bausch Health Cos by 6.4% during the 2nd quarter. State of Wyoming now owns 63,653 shares of the company’s stock worth $424,000 after acquiring an additional 3,855 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.
Insider Buying and Selling
In related news, Director John Paulson purchased 34,721,118 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The stock was bought at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the transaction, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. The trade was a 96.35% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders bought a total of 37,964,167 shares of company stock valued at $333,757,793 in the last ninety days. Company insiders own 19.97% of the company’s stock.
About Bausch Health Cos
(Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
Five stocks we like better than Bausch Health Cos
Should You Add These Warren Buffett Stocks to Your Portfolio?
Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
Investing in the High PE Growth Stocks
Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Compound Interest and Why It Matters When Investing
This ETF Weeds Out Small-Cap Underperformers